| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Profit before tax | -49.2 | -50.3 |
| Net income | -49.2 | -50.3 |
| EPS (diluted, $ a share) | $-0.43 | $-0.45 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: RCKT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Rocket Pharmaceuticals, Inc.: key numbers
- Share price
- $2.16Close, Nov 16
- Market cap
- $241M
- Shares outstanding
- 111.66MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Rocket Pharmaceuticals, Inc.
All →Rocket Pharmaceuticals Insider Sarbani Chaudhuri Sells $11.3K of Stock
Sarbani Chaudhuri sold 4,872 shares of Rocket Pharmaceuticals, Inc. at $2.33 a share, worth $11.3K in total on Nov 9, 2026. Shares held after the trade: 257,937 (-1.9%).
- Value
- $11.3K
- Shares
- 4,872
- Price
- $2.33
- Holding change
- -1.9%
- Trade date
- Nov 9, 2026
Rocket Pharmaceuticals Financial Results
Rocket Pharmaceuticals reported third quarter 2026 financial results, highlighting FDA alignment on the pivotal Phase 2 trial for RP-A501 in Danon disease with dosing completion expected by mid-2027. The company ended the quarter with $279.4 million in cash and investments, which is expected to fund operations into the third quarter of 2028.
- Term
- Q3 2026
“With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027. We are also advancing our broader cardiovascular portfolio, with dosing initiated in the Phase 1 trial of RP-A701 for BAG3-DCM and continued FDA engagement on a potential pivotal study of RP-A601 in PKP2-ACM. Commercial readiness for KRESLADI and activation of our first Qualified Treatment Centers bring us closer to treating eligible children. Our financial resources and the additional flexibility provided by the Hercules facility support these priorities as we work toward our next clinical and commercial milestones.”
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
Rocket Pharmaceuticals General Counsel Martin Wilson Sells $128K of Stock
Martin Wilson, General Counsel, sold 53,389 shares of Rocket Pharmaceuticals, Inc. at $2.39 a share, worth $128K in total on Nov 5, 2026. Shares held after the trade: 545,100 (-8.9%).
- Value
- $128K
- Shares
- 53,389
- Price
- $2.39
- Role
- General Counsel
- Holding change
- -8.9%
- Trade date
- Nov 5, 2026
Rocket Pharmaceuticals $150M Debt Financing with Hercules Capital, Inc.
Rocket Pharmaceuticals entered into a senior secured term loan agreement with Hercules Capital for up to $150.0 million across five tranches. The company received an initial $35.0 million at closing, with subsequent tranches available upon clinical milestones and lender approval to support its Phase 2 study of RP-A501 for Danon disease.
- Value
- $150M
- Counterparty
- Hercules Capital, Inc.
- Term
- Through Oct 2030
Rocket Pharmaceuticals Business Update
Rocket Pharmaceuticals announced alignment with the FDA on the pivotal Phase 2 trial design for RP-A501 in Danon disease, including a 12-patient pivotal population and 12-month co-primary endpoints. The FDA's review of initial safety data from the first three patients supports continued enrollment and dosing under a modified protocol, with completion of dosing expected by mid-2027.
- Counterparty
- FDA